Ken Griffin Ambrx Biopharma Inc. Transaction History

Citadel Advisors LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$9.3 - $16.6 $388,767 - $693,929	41,803 Added 5.75%	768,825 $8.84 Million
Q2 2023 Aug 14, 2023	BUY	$7.66 - $16.46 $152,349 - $327,372	19,889 Added 2.81%	727,022 $12 Million
Q1 2023 May 15, 2023	BUY	$1.46 - $12.54 $1.03 Million - $8.81 Million	702,770 Added 16107.49%	707,133 $6.31 Million
Q4 2022 Feb 14, 2023	SELL	$0.41 - $4.54 $3,178 - $35,198	-7,753 Reduced 63.99%	4,363 $9,000
Q3 2022 Nov 14, 2022	BUY	$1.06 - $2.96 $12,842 - $35,863	12,116 New	12,116 $13,000

31.2K

Ticker AMAM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,618,400
Market Cap $1.08B
Description
Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gas...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.